Next Generation Sequencing (NGS) Informatics Market by Offering (Data Analysis, Interpretation & Reporting, Storage & Computing, LIMS) Application (Diagnostic, Drug Discovery, Precision Medicine, Biomarker Discovery) End User - Global Forecast to 2030

Next Generation Sequencing (NGS) Informatics Market by Offering (Data Analysis, Interpretation & Reporting, Storage & Computing, LIMS) Application (Diagnostic, Drug Discovery, Precision Medicine, Biomarker Discovery) End User - Global Forecast to 2030

Next Generation Sequencing (NGS) Informatics Market by Offering (Data Analysis, Interpretation & Reporting, Storage & Computing, LIMS) Application (Diagnostic, Drug Discovery, Precision Medicine, Biomarker Discovery) End User — Global Forecast to 2030

The global NGS informatics market is projected to reach $4.3 billion by 2030, at a CAGR of 15.4% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the NGS informatics market is driven by increasing R&D investments by pharmaceutical and biotechnology companies, the rising prevalence of cancer and genetic disorders, the growing utilization of NGS in disease diagnostics and precision medicine, technological advancements in NGS informatics solutions, and government initiatives supporting large-scale genomic sequencing projects. However, data confidentiality concerns restrain the growth of this market.

The increasing adoption of NGS informatics tools among hospitals and clinical laboratories and the growing use of bioinformatics and genomic data management solutions for large-scale data analysis and interpretation are expected to create growth opportunities for the players operating in the NGS informatics market. However, the lack of skilled professionals required to operate NGS Informatics tools is a major challenge for market growth.

Based on offering, in 2023, the software segment is expected to account for the largest share of the market. NGS informatics software enables researchers to efficiently analyze, store, and securely share vast amounts of genomic data. With their cost and time-saving capabilities, robust data security measures, and seamless collaboration features, these software solutions enable effective genomic data management, contributing to the large market share of this segment.

Based on application, in 2023, the drug discovery segment is expected to account for the largest share of the market. The growth of this segment is driven by the benefits offered by NGS technology in drug discovery. NGS enables the identification of novel drug targets and the development of therapeutic techniques that target specific genes and proteins, including targeted therapies, gene therapy, and oligonucleotide therapy.

Based on end user, in 2023, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the next generation sequencing (NGS) informatics market. Pharmaceutical & biotechnology companies extensively utilize NGS for high-throughput analysis and genetic-based drug development. The adoption of NGS informatics has enabled efficient management, analysis, and reporting of large volumes of genomic data, thereby supporting remote work and enhancing research capabilities. These factors contribute to the significant market share of this segment.

An in-depth analysis of the geographical scenario of the global NGS informatics market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the NGS informatics market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The factors supporting the largest share of this market are technological advancements in the region, the increasing prevalence of cancer, and increased healthcare care spending. Additionally, the presence of key players, well-established healthcare infrastructure, and government initiatives for NGS-based diagnostic testing also contribute to the large market share of North America.

The key players operating in the global NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Qiagen N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Sapio Sciences, LLC (U.S.), DNASTAR, Inc. (U.S.), Fabric Genomics, Inc. (U.S.), Partek Incorporated (U.S.), and DNAnexus, Inc. (U.S.).

Scope of the Report:

Next Generation Sequencing (NGS) Informatics Market Assessment—by Offering

Software

By Type

Data Analysis Software
Data Interpretation and Reporting Tools
Data Storage and Computing Tools
Laboratory Information Management Systems (LIMS)

By Deployment mode

Web and Cloud-based
On-premise
NGS Informatics Services

Next Generation Sequencing (NGS) Informatics Market Assessment—by Application

Disease Diagnoses
Biomarker Discovery
Drug Discovery
Precision Medicine
Agriculture and Animal Research

Next Generation Sequencing (NGS) Informatics Market Assessment—by End User

Pharmaceutical and Biotechnology Companies
Hospitals & Diagnostic Laboratories
Academic & Research Institutes
Other End Users

Note: Other end users include forensic laboratories & security agencies, food and beverage companies, and agriculture companies.

Next Generation Sequencing (NGS) Informatics Market Assessment—by Geography

North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa

Next Generation Sequencing (NGS) Informatics Market - Report Summary

Report Metrics	Details
Years Considered	2021 - 2030
Base Year	2022
Forecast Period	2023-2030
Page Count	203
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Offering, Application, End User
Regions Covered	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Key Companies Mentioned	Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Qiagen N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Sapio Sciences, LLC (U.S.), DNASTAR, Inc. (U.S.), Fabric Genomics, Inc. (U.S.), Partek Incorporated (U.S.), and DNAnexus, Inc. (U.S.).

FAQs About the Report

What is the focus of the next generation sequencing (NGS) informatics market study?

This study offers a detailed assessment of the next generation sequencing (NGS) informatics market and analyzes the market sizes & forecasts based on offering, application, and end user. This report also involves the value analysis of various segments and subsegments of the next generation sequencing (NGS) informatics market at the regional and country levels.

What is the revenue generated from selling next generation sequencing (NGS) informatics across the globe? At what rate is their demand expected to grow for the next 5-7 years?

The next generation sequencing (NGS) informatics market is projected to reach $4.3 billion by 2030, at a CAGR of 15.4% during the forecast period.

Based on offering, which segment is expected to hold the largest share of the market in 2023?

The software segment is expected to account for the largest share of the market in 2023.

Which application segment is expected to hold the largest share of the market in 2023?

The drug discovery segment is expected to hold the largest share of the market in 2023. The large market share of this segment is attributed to the increasing applications of NGS in various clinical and research areas, the rise in global pharmaceutical research and development activities, and the growing need for data management, analysis, and storage in drug discovery.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the global next generation sequencing (NGS) informatics market?

The growth of the NGS informatics market is driven by increasing R&D investments by pharmaceutical and biotechnology companies, the rising prevalence of cancer and genetic disorders, the growing utilization of NGS in disease diagnostics and precision medicine, technological advancements in NGS informatics solutions, and government initiatives supporting large-scale genomic sequencing projects.

Furthermore, the increasing adoption of NGS informatics tools among hospitals and clinical laboratories and the growing use of bioinformatics and genomic data management solutions for large-scale data analysis and interpretation are expected to create growth opportunities for the players operating in the NGS informatics market.

Who are the major players operating in the global next generation sequencing (NGS) informatics market?

The key players profiled in the next generation sequencing (NGS) informatics market study are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Qiagen N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Sapio Sciences, LLC (U.S.), DNASTAR, Inc. (U.S.), Fabric Genomics, Inc. (U.S.), Partek Incorporated (U.S.), and DNAnexus, Inc. (U.S.).

Which regions/countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?

Emerging economies such as China and India are projected to offer significant growth opportunities to the market players due to rising investments in the healthcare sector and increasing genomic projects in these countries.